SCHEMBL22907331

SCHEMBL22907331

COC(=O)c1ccc(OCCOCCBr)cc1C(=O)OC

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NPC1 O15118 1/20 0.50
KDM4E B2RXH2 4/20 0.40
TDP1 Q9NUW8 4/20 0.40
RARA P10276 1/20 0.40
RARB P10826 1/20 0.40
MAOB P27338 5/20 0.39
MAOA P21397 4/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29548458 1.00 MAPT (0.50) MAPTRAB9ASMN1; SMN2NPC1KDM4E
SCHEMBL23250015 0.91 MAPT (0.49) MAPTRAB9AKDM4ETDP1MAOB
SCHEMBL21752071 0.87 MAPT (0.49) MAPTRAB9ASMN1; SMN2KDM4ETDP1
SCHEMBL21751858 0.87 MAPT (0.49) MAPTRAB9ASMN1; SMN2KDM4ETDP1
SCHEMBL27098563 0.87 MAPT (0.49) MAPTRAB9AKDM4ETDP1RARA
SCHEMBL26017715 0.87 MAPT (0.49) MAPTRAB9AKDM4ETDP1RARA
SCHEMBL22906989 0.87 MAPT (0.49) MAPTRAB9ASMN1; SMN2KDM4ETDP1
SCHEMBL26017933 0.87 MAPT (0.49) MAPTRAB9AKDM4ETDP1RARA
SCHEMBL20129246 0.86 RARB (0.54) MAPTRAB9ASMN1; SMN2KDM4ETDP1
SCHEMBL21771288 0.85 MAPT (0.44) MAPTRAB9ASMN1; SMN2KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN MAPT 1/4885RAB9A 1429/4885SMN1; SMN2 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.